Humana Inc (NYSE:HUM) – Leerink Swann issued their Q1 2018 earnings per share (EPS) estimates for Humana in a research report issued on Thursday. Leerink Swann analyst A. Gupte expects that the insurance provider will earn $3.25 per share for the quarter. Leerink Swann currently has a “Outperform” rating and a $300.00 target price on the stock. Leerink Swann also issued estimates for Humana’s Q2 2018 earnings at $4.13 EPS, Q3 2018 earnings at $4.02 EPS, Q4 2018 earnings at $2.59 EPS and FY2021 earnings at $21.50 EPS.

Other equities research analysts have also recently issued reports about the company. Oppenheimer lifted their price objective on Humana from $275.00 to $305.00 and gave the stock an “outperform” rating in a research note on Thursday. Deutsche Bank lifted their price objective on Humana from $259.00 to $270.00 and gave the stock a “hold” rating in a research note on Friday. Credit Suisse Group began coverage on Humana in a report on Thursday, November 2nd. They set a “neutral” rating and a $256.00 target price on the stock. Zacks Investment Research lowered Humana from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 17th. Finally, ValuEngine lowered Humana from a “buy” rating to a “hold” rating in a report on Tuesday, December 19th. Eight research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $269.68.

Shares of Humana (NYSE HUM) opened at $265.32 on Friday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.61 and a current ratio of 1.85. Humana has a 52 week low of $203.36 and a 52 week high of $293.35. The company has a market capitalization of $37,843.64, a price-to-earnings ratio of 15.91, a P/E/G ratio of 1.54 and a beta of 0.93.

Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, February 7th. The insurance provider reported $2.06 EPS for the quarter, topping analysts’ consensus estimates of $2.00 by $0.06. Humana had a return on equity of 16.13% and a net margin of 4.55%. The business had revenue of $13.19 billion during the quarter, compared to analysts’ expectations of $13.14 billion. During the same period in the previous year, the firm earned $2.34 earnings per share. The firm’s quarterly revenue was up 2.4% compared to the same quarter last year.

The company also recently declared a quarterly dividend, which will be paid on Friday, April 27th. Stockholders of record on Friday, March 30th will be issued a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a dividend yield of 0.75%. This is a positive change from Humana’s previous quarterly dividend of $0.40. The ex-dividend date of this dividend is Wednesday, March 28th. Humana’s payout ratio is 9.59%.

Humana announced that its Board of Directors has approved a share repurchase plan on Thursday, December 14th that permits the company to repurchase $3.00 billion in outstanding shares. This repurchase authorization permits the insurance provider to repurchase shares of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s board of directors believes its stock is undervalued.

In other news, SVP Jody L. Bilney sold 7,054 shares of the business’s stock in a transaction dated Monday, December 18th. The stock was sold at an average price of $247.89, for a total value of $1,748,616.06. Following the sale, the senior vice president now directly owns 11,704 shares in the company, valued at $2,901,304.56. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Brian P. Leclaire sold 1,679 shares of the business’s stock in a transaction dated Thursday, December 21st. The shares were sold at an average price of $245.97, for a total value of $412,983.63. Following the completion of the sale, the senior vice president now owns 9,888 shares in the company, valued at $2,432,151.36. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 10,115 shares of company stock worth $2,501,627. Corporate insiders own 0.80% of the company’s stock.

Institutional investors have recently modified their holdings of the company. WFG Advisors LP lifted its holdings in shares of Humana by 4.5% in the second quarter. WFG Advisors LP now owns 469 shares of the insurance provider’s stock valued at $113,000 after purchasing an additional 20 shares in the last quarter. Fieldpoint Private Securities LLC bought a new stake in shares of Humana in the third quarter valued at about $115,000. ClariVest Asset Management LLC bought a new stake in shares of Humana in the third quarter valued at about $144,000. Daiwa SB Investments Ltd. lifted its holdings in shares of Humana by 44.9% in the fourth quarter. Daiwa SB Investments Ltd. now owns 710 shares of the insurance provider’s stock valued at $176,000 after purchasing an additional 220 shares in the last quarter. Finally, Virtu Financial LLC bought a new stake in shares of Humana in the fourth quarter valued at about $204,000. Institutional investors own 94.39% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this news story can be read at https://www.thecerbatgem.com/2018/02/10/humana-inc-hum-expected-to-post-q1-2018-earnings-of-3-25-per-share.html.

Humana Company Profile

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Earnings History and Estimates for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.